Stocks · News reference
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst
Guggenheim Downgrades Tenax Therapeutics to Neutral
Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.
Reported Earlier, Tenax Reports New Phase 3 Data Supporting TNX-103 In Pulmonary Hypertension Patients